Displaying drugs 11326 - 11350 of 11617 in total
Tiragolumab
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Investigational
Matched Description: … Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab …
BBM-H901
BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.
Investigational
Matched Description: … BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua …
Puromycin
Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.
Experimental
Matched Description: … It is utilized as a selective agent in laboratory cell cultures. …
Theralizumab
Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]
Investigational
Matched Description: … Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and …
Velsecorat
Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma).
Investigational
Matched Description: … Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to …
Tasosartan
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
YSIL6
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Investigational
Matched Description: … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid …
T487
T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Investigational
Matched Description: … T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. …
Delgocitinib
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
Investigational
Matched Description: … Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a …
RGX-501
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional …
CVT-6883
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Description: … CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics …
Clobutinol
Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Withdrawn
Matched Description: … Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. …
Molibresib
Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
Investigational
Matched Description: … Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate …
FX06
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
Investigational
Matched Description: … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). …
Ridaforolimus
Investigational
Lobeline
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral …
D-JNKI-1
A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of oxidative stress.
Investigational
Matched Description: … A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic …
PI-166
PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Investigational
Matched Description: … PI-166 is a small organic compound with specific avidity to liver cancer cells. …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a …
TMC-649128
TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin).
Investigational
Matched Description: … TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype …
PF-04856884
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. …
Irofulven
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers....
Investigational
Matched Description: … A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more ... than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track …
Displaying drugs 11326 - 11350 of 11617 in total